Introduction: Sodium-glucose co-transporter 2 inhibitors (SGLT-2i) increase urinary glucose excretion through a reduced renal glucose reabsorption. We plan to perform a systematic review of SGLT-2i for treatment of type 2 diabetes.
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INTRODUCTION
Type 2 diabetes is a metabolic disease associated with obesity, dyslipidaemia and hypertension. Patients with type 2 diabetes are characterised by defective insulin secretion, insulin resistance, inappropriate glucagon secretion and an impaired incretin effect resulting in fasting and postprandial hyperglycaemia. 1 Hyperglycaemia with elevated levels of glycated haemoglobin (HbA1c) predicts microvascular and macrovascular complications. 2 Although improved metabolic control is associated with reduced morbidity and mortality, 3 recent studies show that intensive glucose lowering treatments may harm some patients. [4] [5] [6] [7] As a consequence, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend individualisation of the treatment. 8 Drugs with complementary mechanisms of action are recommended with metformin as a first-line therapy. As β-cell function declines, a number of patients fail to achieve their glycaemic target and maintenance of glucose control often necessitates several add-on therapies. 8 Current oral medications endorsed by ADA and EASD treatment algorithms for treating patients with type 2 diabetes, that is, metformin, sulfonylureas, dipeptidyl peptidase 4 inhibitors and thiazolidinediones, act by increasing insulin secretion or sensitising tissues to insulin action. Treatment strategies with insulin-independent pathways could therefore be advantageous.
Strengths and limitations of this study
▪ We have the knowledge and experience on how to conduct a systematic review and meta-analysis. ▪ We limit our analyses to only include trials on the relevant daily doses of SGLT-2i to give the evidence-based clinician a more useful answer. ▪ A possible limitation might be the access to data from the randomised clinical trials we plan to include in the study.
Sodium-glucose co-transporter 2 inhibitors (SGLT-2i) represent a new class of drugs that inhibit glucose reabsorption in the proximal tubules of the kidneys. As a result, urinary glucose excretion is increased, which in turn reduces the amount of circulating glucose and improves glycaemic control. The effect is not associated with insulin secretion or action. 9 In clinical trials, SGLT-2i (in monotherapy or combined with metformin, sulfonylureas, pioglitazone or insulin) seems to improve glycaemic control in type 2 diabetes. [10] [11] [12] [13] [14] In 2013 and 2014, two STGL-2i, canagliflozin and dapagliflozin, were approved by the US Food and Drug Administration (FDA) 15 16 and the European Medicine Agency (EMA) for the treatment of patients with type 2 diabetes. 17 18 None of the individual clinical trials on SGLT-2i provide definite conclusions regarding efficacy and safety, and so far the current guidelines for the management of type 2 diabetes do not include SGLT-2i. 8 In order to provide robust evidence for the efficacy and safety of SGLT-2i, we plan to perform a systematic review with meta-analyses of randomised controlled trials (RCTs). Previous systematic reviews on SGLT-2i 19-24 used a pragmatic approach and included trials irrespective of the dosing or duration of follow-up. We restricted our analyses to 'clinically relevant' trials, that is, trials assessing doses and interventions that we use in clinical practice. We therefore limit our analyses to include trials on the recommended daily dose, clinical relevant compounds and with sufficient follow-up to assess the clinical effects. This approach means that smaller trials, such as dose finding trials, will not be included. We believe that this approach will give the evidence-based clinician a clearer and more useful answer. Doses that are not clinically relevant may underestimate or overestimate the beneficial and potentially harmful effects of SGLT-2i. Therefore our data may provide a more accurate answer that may be used in clinical practice.
OBJECTIVES
The primary objective of this systematic review is to evaluate the effects of SGLT-2i that are approved (dapagliflozin and canagliflozin) or are in late clinical development (empagliflozin) in Europe and the USA. To increase external validity, we plan to evaluate doses that are currently recommended by FDA and/or EMA 17 25 26 as a maximum daily dose and therefore only include trials with these daily doses (canagliflozin 300 mg, dapagliflozin 10 mg and empagliflozin 25 mg). Our primary objective will be to assess the impact on glycaemic control (HbA1c).
METHODS
The reporting of the review will follow the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement. 27 Criteria for considering studies for this review Studies The review will include RCTs irrespective of blinding and language.
Participants
Adult patients (at least 18 years of age) of both genders with type 2 diabetes will be included.
Duration
Since red blood cells survive for 8-12 weeks, the trials should last for at least 12 weeks to evaluate the effect of SGLT-2i on HbA1c.
Interventions
The intervention comparisons will constitute SGLT-2i (dapagliflozin, canagliflozin and empagliflozin) versus placebo, other oral antidiabetic drugs or insulin. Co-interventions with other antidiabetic agents will be allowed if administered to the intervention and control groups.
Types of outcome measures
The following outcome measures will be assessed Primary outcome measure ▸ HbA1c
Secondary outcome measures ▸ Body weight and body mass index (BMI) ▸ Fasting plasma glucose ▸ Lipid profile (low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol and triglyceride) ▸ Systolic and diastolic blood pressure ▸ Liver and kidney blood tests (creatinine and uric acid) ▸ Urinary albumin ▸ Adverse events (any adverse events, urinary tract infections, genital tract infections, hypoglycaemia, hypotension, total withdrawals) Search methods for identification of studies All authors will participate in the identification and selection of trials. Excluded trials will be listed with the reason for exclusion. Authors will extract data in an independent manner. Eligible trials will be identified through electronic and manual searches. Electronic searches will be performed in MEDLINE ((Sodiumglucose (All Fields) AND co-transporter (All Fields)) OR ("2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol" (Supplementary Concept) OR "2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6hydroxymethyltetrahydro-2H-pyran-3,4,5-triol" (All Fields) OR "dapagliflozin" (All Fields)) OR ("canagliflozin" (Supplementary Concept) OR "canagliflozin" (All Fields)) OR ("empagliflozin" (Supplementary Concept) OR "empagliflozin" (All Fields)) OR Remogliflozin (All Fields) OR ("sergliflozin" (Supplementary Concept) OR "sergliflozin" (All Fields)) OR ("6-((4-ethylphenyl)methyl)-3′,4′,5′,6′-tetrahydro-6′-(hydroxymethyl)spiro(isobenzofuran-1(3H),2′-(2H)pyran)-3′,4′,5′-triol" (Supplementary Concept) OR "6-((4-ethylphenyl)methyl)-3′,4′,5′,6′-tetrahydro-6′-(hydroxymethyl)spiro(isobenzofuran-1(3H),2′-(2H) pyran)-3′,4′,5′-triol" (All Fields) OR "tofogliflozin" (All Fields))), Cochrane Library, Embase and Web of Science. Additional manual searches will be performed in reference lists of relevant papers, correspondence with experts, the pharmaceutical companies producing SGLT-2i and the WHO Trial Search Database. 28 Data collection and analysis Two authors (HS and MC) will independently extract data and resolve disagreements through discussion before analysis. In the case of unresolved matters, a third party (TV, FKK or LLG) will be involved. If necessary data are not included in the published trial reports, authors of included trials will be contacted for additional information.
Selection of studies Trials identified through searches will be listed and selected for inclusion according to the aforementioned criteria.
Data extraction
Extraction forms developed for the study will be used and the following data will be extracted: trial characteristics (number of clinical sites, country of origin and funding), intervention characteristics (type, dose and duration of interventions applied), patient characteristics (inclusion criteria, background treatment, mean age, proportion of men, duration of type 2 diabetes, body weight, BMI, baseline systolic and diastolic blood pressure, urinary albumin baseline HbA1c, baseline blood tests, fasting plasma glucose, LDL-cholesterol, HDL-cholesterol and triglyceride alanine amino transferase, alkaline phosphatase, creatinine and urate).
Assessment of risk of bias in included studies
The bias risk assessment will follow the recommendations described in the Cochrane Handbook for Systematic Reviews of Interventions and includes: ▸ Randomisation (selection bias): randomisation methods will be extracted as the primary measure of bias control. 29 Methodological quality in randomisation methods will be based on allocation sequence generation (adequate if based on a table of random numbers, computer-generated random numbers or similar) and allocation concealment (adequate if randomisation was performed through serially numbered opaque sealed envelopes, a central independent unit, identically appearing coded drug containers or similar).
▸ Blinding ( performance and detection bias): we will extract data on whether single or double blinding was performed, the method of blinding (eg, use of placebo) and the persons who were blinded with regard to the interventions assessed (eg, healthcare providers or patients). ▸ Incomplete outcome data (attrition bias): the extent to which all patients lost to follow-up are accounted for. ▸ Outcome reporting (reporting bias): the extent to which clinically relevant outcome measures are reported and differences between trial protocols and subsequent reports will be evaluated as a marker of reporting bias. ▸ Other bias: any other apparent biases will be evaluated.
Statistical analyses
Analyses will be performed in RevMan 30 and Stata V.13 (STATA Corp, College Station, Texas, USA). They will be based on individual patient data when available or on published data. I 2 will be used as a measure of heterogeneity. I 2 values below 30% will be defined as unimportant, 30-50% as moderate, 50-75% as substantial and >75% as considerable heterogeneity. Irrespective of the statistical heterogeneity, the fixed effects and random effects models will be used to test the robustness of the results. We will only report the results of the random effects meta-analyses if the results differ from those of the fixed effects models. Publication bias and other small study effects will be evaluated based on regression analysis (Egger's or Harbord's test). We plan to perform subgroup and meta-regression analyses based on treatment combinations as well as baseline patient characteristics. Differences between subgroups will be explored using tests for subgroup differences expressed as p values. The subgroup analyses will evaluate the influence of the type of data (individual patient data or published data), the control groups (stratified by the type of intervention allocated to the control group) and collateral interventions (interventions administered to both allocation groups). We will also perform meta-regression analyses to evaluate the potential influence of glycaemic control at baseline, duration of diabetes and baseline body weight. In sensitivity analyses, we will evaluate the intervention effect in: 1) patients who are of normal weight (defined as a maximum BMI of 25 kg/m 2 ), 2) trials published as full paper articles and 3) trials with a low risk of bias.
Measures of treatment effect
Dichotomous data will be analysed using risk differences and continuous data using mean differences, both with 95% CIs.
Unit of analyses issues
For trials presenting data from more than one treatment period (eg, 26 and 52 weeks), data from the longest treatment period will be used. On the basis of the primary outcome measure, we will only use data from the first period of cross-over trials.
Dealing with missing data Intention-to-treat analyses including all patients randomised will be performed. For patients with missing data, we will perform sensitivity analyses with simple imputation (counting patients as failures or successes).
ETHICS AND DISSEMINATION
The study will evaluate the clinical effect of SGLT-2i in patients with type 2 diabetes based on the available published and unpublished clinical trial data and thereby potentially improve the clinical knowledge on and management of type 2 diabetes.
